ALK and non-small cell lung carcinoma: Based on the results of CheckMate 017 and CheckMate 057 [25–27], nivolumab was recommended as the second-line treatment regimen for patients with NSCLC without actionable genetic mutations, including EGFR and ALK, after progressing from first-line platinum-containing chemotherapy [19].